PHASE

A PHArmacogenomic study of Statins in the Elderly at risk for cardiovascular disease

Coordinatore	ACADEMISCH ZIEKENHUIS LEIDEN    more  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Ms. Nome: Tineke Cognome: Sanches Email: send email Telefono: +31 71 5262088 Fax: +31 71 5248117
Nazionalità Coordinatore	Netherlands [NL]
Sito del progetto	http://www.lumc.nl/con/9099/100426014917221/
Totale costo	3˙766˙919 €
EC contributo	2˙858˙188 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-B
Funding Scheme	CP-FP
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-01-01   -   2012-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Ms. Nome: Tineke Cognome: Sanches Email: send email Telefono: +31 71 5262088 Fax: +31 71 5248117	NL (LEIDEN)	coordinator	2˙426˙140.00
2	UNIVERSITY OF GLASGOW  Organization address address: University Avenue city: GLASGOW postcode: G12 8QQ contact info Titolo: Dr. Nome: Joseph Cognome: Galloway Email: send email Telefono: +44 141 3303884 Fax: +44 141 3305611	UK (GLASGOW)	participant	358˙140.00
3	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Ms. Nome: Mary Cognome: Cusack Email: send email Telefono: +353 21 4902347 Fax: +353 21 4903018	IE (CORK)	participant	73˙908.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cardiovascular disease is the leading cause of death in industrialized countries. The prevention of cardiovascular disease is critically dependent on lipid lowering therapy, which includes the 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Although statins are the most prescribed class of drugs worldwide, and therapy is generally associated with a reduction in risk for cardiovascular events by 20-30%, clinical response can be highly variable and adverse effects occur in a minority of patients. Recent research has provided evidence that in many cases, genetic variation contributes to this variable drug response. Research efforts should be made in analyzing the differences in genetic background to identify which genetic variation accounts for the variability in clinical response. Here we present a study that will establish in a large prospective randomized clinical trial with statin allocation which genetic variation is responsible for the variation in drug response. In 5804 participants of the PROspective Study of Pravastatin in the Elderly at risk (PROSPER) we will perform a genome-wide scan to assess the genetic variation responsible for variation in lowering low-density lipoprotein levels, in clinical outcome and for the occurrence of adverse effects. The unique character of the PROSPER study is that the study is randomized in three European countries, therefore all associations can be replicated in these countries. Positive associations will be confirmed in two comparable large clinical trials, the WOSCOPS and the CARE study. Cardiovascular pharmacogenomics will lead to improvements in the use of personalized therapy based on an individual’s genetic make-up. Non-responders or subjects who experience adverse effects will not be indicated for statin treatment when they are identified. This will increase the quality of life for many elderly people with polypharmacy and comorbidity and reduce costs for healthcare organizations.'

Introduzione (Teaser)

Pharmacogenomics focuses on unravelling the genetic determinants of variable drug responses, both in intended, beneficial effects and unintended, adverse effects. The PHASE consortium performed a genome-wide association study to assess the genetic variation responsible for the variability in statin drug response in patients with cardiovascular events.